List of works - Martin Hoyle

A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients

scientific article published on 25 April 2015

A search theory model of patch-to-patch forager movement with application to pollinator-mediated gene flow.

scientific article published in May 2007

A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome

scientific article

Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis

scientific article published on January 1, 2011

Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal

scientific article

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

scientific article

Causes of the species-area relationship by trophic level in a field-based microecosystem

scientific article published on 01 June 2004

Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal

scientific article published on 01 April 2018

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

scientific article published on 12 October 2011

Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.

scientific article

Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.

scientific article published on 25 September 2009

Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.

scientific article published on 25 September 2009

Cytokine response profiles predict species-specific infection patterns in human GI nematodes

article

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

scientific article published on January 2012

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

scientific article published on 01 August 2018

Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.

scientific article published in March 2018

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis

scientific article published on 01 September 2018

Evolution of a cost-utility model of donepezil for Alzheimer's disease.

scientific article published on 20 March 2013

Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.

scientific article

Future drug prices and cost-effectiveness analyses.

scientific article

Historical Lifetimes of Drugs in England: Application to Value of Information and Cost-Effectiveness Analyses ⬇️

scientific article published on September 3, 2010

Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model

scientific article

Improved curve fits to summary survival data: application to economic evaluation of health technologies.

scientific article

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

scientific article published on 17 September 2013

Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK ⬇️

scientific article published on May 1, 2011

Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.

scientific article published on 15 September 2017

Reply: SUN BEVIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

scientific article published on 5 January 2010

Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.

scientific article published on September 2009

T helper cell type 2 responsiveness predicts future susceptibility to gastrointestinal nematodes in humans.

scientific article

The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer [...]

scientific article

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and e

scientific article

The effect of wind direction on cross-pollination in wind-pollinated GM crops

scientific article published on 01 June 2007

The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model.

scientific article published on September 2009

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model ⬇️

scientific article published on January 1, 2012

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model

scientific article

The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model.

scientific article

Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation

scientific article published on 01 March 2019

Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts.

scientific article

List of works by Martin Hoyle

A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients

A search theory model of patch-to-patch forager movement with application to pollinator-mediated gene flow.

A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome

Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis

Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

Causes of the species-area relationship by trophic level in a field-based microecosystem

Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.

Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.

Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.

Cytokine response profiles predict species-specific infection patterns in human GI nematodes

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis

Evolution of a cost-utility model of donepezil for Alzheimer's disease.

Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.

Future drug prices and cost-effectiveness analyses.

Historical Lifetimes of Drugs in England: Application to Value of Information and Cost-Effectiveness Analyses ⬇️

Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model

Improved curve fits to summary survival data: application to economic evaluation of health technologies.

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK ⬇️

Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.

Reply: SUN BEVIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.

T helper cell type 2 responsiveness predicts future susceptibility to gastrointestinal nematodes in humans.

The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer [...]

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and e

The effect of wind direction on cross-pollination in wind-pollinated GM crops

The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model ⬇️

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model

The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model.

Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation

Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts.